Europe Uterine Cancer Drug Market - Industry Trends and Forecast to 2030

Description

List of Tables

The Europe uterine cancer drugs market is expected to reach USD 1,251,870.80 thousand by 2030 from USD 684,672.98 thousand in 2022, growing at a CAGR of 8.4% during the forecast period of 2023 to 2030.

Market Segmentation

Europe Uterine Cancer Drugs Market, By Cancer Type (Endometrial Cancer and Uterine Sarcoma), Treatment Type (Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy, and Others), Drug Type (Generic and Branded), Age Group (Adults and Geriatric), Route of Administration (Oral and Parenteral), End-User (Hospitals, Cancer Centers, Specialty Clinics, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, and Rest of Europe) - Industry Trends and Forecast to 2030.

Overview of Europe Uterine Cancer Drugs Market Dynamics

Driver
Rising incidence of uterine cancer
Restraint
High cost of uterine cancer treatment
Opportunity
Advancement in genomic profiling and biomarker discovery

Market Players

Some of the major market players operating in the Europe uterine cancer drugs market are:

Merck & Co., Inc.
Sanofi
Eisai Co., Ltd.
Pfizer Inc.
Teva Pharmaceuticals USA, Inc.
Baxter
Hikma Pharmaceuticals PLC
Viatris Inc.
Sun Pharmaceutical Industries Ltd.
Eli Lilly and Company
GSK plc.
Amneal Pharmaceuticals LLC.
Getwell Oncology

1 INTRODUCTION 22

1.1 OBJECTIVES OF THE STUDY 22
1.2 MARKET DEFINITION 22
1.3 OVERVIEW OF THE EUROPE UTERINE CANCER DRUGS MARKET 22
1.4 LIMITATIONS 24
1.5 MARKETS COVERED 24

2 MARKET SEGMENTATION 27

2.1 MARKETS COVERED 27
2.2 GEOGRAPHICAL SCOPE 28
2.3 YEARS CONSIDERED FOR THE STUDY 28
2.4 CURRENCY AND PRICING 28
2.5 DBMR TRIPOD DATA VALIDATION MODEL 29
2.6 MULTIVARIATE MODELLING 32
2.7 CANCER TYPE LIFELINE CURVE 32
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 33
2.9 DBMR MARKET POSITION GRID 34
2.10 MARKET END USER COVERAGE GRID 35
2.11 VENDOR SHARE ANALYSIS 36
2.12 SECONDARY SOURCES 37
2.13 ASSUMPTIONS 37

3 EXECUTIVE SUMMARY 38

4 PREMIUM INSIGHTS 41

5 EUROPE UTERINE CANCER DRUGS MARKET, REGULATORY FRAMEWORK 42

5.1 OVERVIEW 42
5.2 REGULATIONS IN EUROPE 43

6 MARKET OVERVIEW 44

6.1 DRIVERS 46
- 6.1.1 RISING INCIDENCE OF UTERINE CANCER WORLDWIDE 46
- 6.1.2 GROWING ADVANCEMENTS IN TARGETED THERAPY FOR UTERINE CANCER 47
- 6.1.3 RISING AWARENESS OF UTERINE CANCER 48
- 6.1.4 RISING COLLABORATIONS AND PARTNERSHIPS AMONG LEADING PLAYERS 49
6.2 RESTRAINTS 50
- 6.2.1 HIGH COST OF UTERINE CANCER TREATMENT 50
- 6.2.2 SIDE EFFECTS AND TOXICITY ASSOCIATED WITH CANCER DRUGS 50
6.3 OPPORTUNITIES 52
- 6.3.1 ADVANCEMENTS IN GENOMIC PROFILING AND BIOMARKER DISCOVERY 52
- 6.3.2 GROWING R&D ACTIVITIES FOR UTERINE CANCER TREATMENT 53
6.4 CHALLENGES 54
- 6.4.1 REGULATORY HURDLES IN THE UTERINE CANCER DRUGS MARKET 54
- 6.4.2 DRUG RESISTANCE IN THE TREATMENT OF UTERINE CANCER 55

7 EUROPE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE 56

7.1 OVERVIEW 57
7.2 ENDOMETRIAL CANCER 60
- 7.2.1 UTERINE CARCINOSARCOMA 60
- 7.2.2 SEROUS ADENOSARCOMA 60
- 7.2.3 ADENOSQUAMOUS CARCINOMA 60
- 7.2.4 OTHER 60
7.3 UTERINE SARCOMA 61
- 7.3.1 UTERINE LEIOMYOSARCOMA 61
- 7.3.2 ENDOMETRIAL STROMAL SARCOMAS 61
- 7.3.3 UNDIFFERENTIATED SARCOMA 61

8 EUROPE UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE 62

8.1 OVERVIEW 63
8.2 CHEMOTHERAPY 66
- 8.2.1 PACLITAXEL 67
- 8.2.2 CARBOPLATIN 67
- 8.2.3 CISPLATIN 67
- 8.2.4 DOXORUBICIN 67
- 8.2.5 DOCETAXEL 67
- 8.2.6 OTHERS 67
8.3 IMMUNOTHERAPY 68
8.4 HORMONE THERAPY 68
- 8.4.1 PROGESTINS 69
  - 8.4.1.1 MEDROXYPROGESTERONE ACETATE 69
  - 8.4.1.2 OTHERS 69
- 8.4.2 AROMATASE INHIBITORS 70
  - 8.4.2.1 LETRAZOLE 70
  - 8.4.2.2 ANASTRAZOLE 70
  - 8.4.2.3 EXEMESTANE 70
- 8.4.3 LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS 71
  - 8.4.3.1 GOSERELIN 71
  - 8.4.3.2 LEUPROLIDE 71
- 8.4.4 OTHERS 71
8.5 TARGETED THERAPY 72
- 8.5.1 LENVATINAB 72
- 8.5.2 BEVACIZUMAB 72
- 8.5.3 MTOR INHIBITORS 72
  - 8.5.3.1 EVEROLIMUS 72
  - 8.5.3.2 TEMSIROLIMUS 73
8.6 OTHERS 73

9 EUROPE UTERINE CANCER DRUGS MARKET, BY DRUG TYPE 74

9.1 OVERVIEW 75
9.2 GENERICS 78
9.3 BRANDED 78
- 9.3.1 KEYTRUDA 78
- 9.3.2 LENVIMA 78
- 9.3.3 PROVERA 78
- 9.3.4 TEMODAR 78
- 9.3.5 JEMPERLI 79
- 9.3.6 OTHERS 79

10 EUROPE UTERINE CANCER DRUGS MARKET, BY AGE GROUP 80

10.1 OVERVIEW 81
10.2 GERIATRIC 84
10.3 ADULTS 84

11 EUROPE UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION 85

11.1 OVERVIEW 86
11.2 PARENTERAL 89
11.3 ORAL 89

12 EUROPE UTERINE CANCER DRUGS MARKET, BY END USER 90

12.1 OVERVIEW 91
12.2 HOSPITALS 94
- 12.2.1 PRIVATE 94
- 12.2.2 PUBLIC 94
12.3 CANCER CENTERS 95
12.4 SPECIALTY CLINICS 95
12.5 OTHERS 95

13 EUROPE UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL 96

13.1 OVERVIEW 97
13.2 DIRECT TENDER 100
13.3 RETAIL SALES 100
- 13.3.1 HOSPITAL PHARMACY 100
- 13.3.2 RETAIL PHARMACY 100
- 13.3.3 ONLINE PHARMACY 100
13.4 OTHERS 100

14 EUROPE UTERINE CANCER DRUGS MARKET, BY COUNTRY 101

14.1 EUROPE 101
- 14.1.1 GERMANY 104
- 14.1.2 U.K. 110
- 14.1.3 FRANCE 115
- 14.1.4 RUSSIA 120
- 14.1.5 ITALY 125
- 14.1.6 SPAIN 130
- 14.1.7 TURKEY 135
- 14.1.8 BELGIUM 140
- 14.1.9 NETHERLANDS 146
- 14.1.10 SWITZERLAND 151
- 14.1.11 REST OF EUROPE 157

15 EUROPE UTERINE CANCER DRUGS MARKET, COMPANY LANDSCAPE 158

15.1 COMPANY SHARE ANALYSIS: EUROPE 158

16 SWOT ANALYSIS 159

17 COMPANY PROFILES 160

17.1 MERCK & CO., INC. 160
- 17.1.1 COMPANY SNAPSHOT 160
- 17.1.2 REVENUE ANALYSIS 160
- 17.1.3 PRODUCT PORTFOLIO 161
- 17.1.4 RECENT DEVELOPMENT 161
17.2 SANOFI 163
- 17.2.1 COMPANY SNAPSHOT 163
- 17.2.2 REVENUE ANALYSIS 163
- 17.2.3 PRODUCT PORTFOLIO 164
- 17.2.4 RECENT DEVELOPMENT 164
17.3 EISAI CO., LTD. 165
- 17.3.1 COMPANY SNAPSHOT 165
- 17.3.2 REVENUE ANALYSIS 165
- 17.3.3 PRODUCT PORTFOLIO 166
- 17.3.4 RECENT DEVELOPMENT 166
- 17.3.5 RECENT DEVELOPMENT 166
17.4 PFIZER INC. 167
- 17.4.1 COMPANY SNAPSHOT 167
- 17.4.2 REVENUE ANALYSIS 167
- 17.4.3 PRODUCT PORTFOLIO 168
- 17.4.4 RECENT DEVELOPMENT 169
17.5 TEVA PHARMACEUTICALS USA, INC. 170
- 17.5.1 COMPANY SNAPSHOT 170
- 17.5.2 REVENUE ANALYSIS 170
- 17.5.3 PRODUCT PORTFOLIO 171
- 17.5.4 RECENT DEVELOPMENT 171
17.6 AMNEAL PHARMACEUTICALS LLC 172
- 17.6.1 COMPANY SNAPSHOT 172
- 17.6.2 REVENUE ANALYSIS 172
- 17.6.3 PRODUCT PORTFOLIO 173
- 17.6.4 RECENT DEVELOPMENT 173
17.7 BAXTER 174
- 17.7.1 COMPANY SNAPSHOT 174
- 17.7.2 REVENUE ANALYSIS 174
- 17.7.3 PRODUCT PORTFOLIO 175
- 17.7.4 RECENT DEVELOPMENT 175
17.8 ELI LILLY AND COMPANY 176
- 17.8.1 COMPANY SNAPSHOT 176
- 17.8.2 REVENUE ANALYSIS 176
- 17.8.3 PRODUCT PORTFOLIO 177
- 17.8.4 RECENT DEVELOPMENT 177
17.9 GETWELL ONCOLOGY 178
- 17.9.1 COMPANY SNAPSHOT 178
- 17.9.2 PRODUCT PORTFOLIO 178
- 17.9.3 RECENT DEVELOPMENT 180
17.10 GSK PLC. 181
- 17.10.1 COMPANY SNAPSHOT 181
- 17.10.2 REVENUE ANALYSIS 182
- 17.10.3 PRODUCT PORTFOLIO 182
- 17.10.4 RECENT DEVELOPMENT 182
17.11 HIKMA PHARMACEUTICALS PLC 184
- 17.11.1 COMPANY SNAPSHOT 184
- 17.11.2 REVENUE ANALYSIS 184
- 17.11.3 PRODUCT PORTFOLIO 185
- 17.11.4 RECENT DEVELOPMENT 185
17.12 SUN PHARMACEUTICAL INDUSTRIES LTD. 186
- 17.12.1 COMPANY SNAPSHOT 186
- 17.12.2 REVENUE ANALYSIS 186
- 17.12.3 PRODUCT PORTFOLIO 187
- 17.12.4 RECENT DEVELOPMENT 188
17.13 VIATRIS INC. 189
- 17.13.1 COMPANY SNAPSHOT 189
- 17.13.2 REVENUE ANALYSIS 189
- 17.13.3 PRODUCT PORTFOLIO 190
- 17.13.4 RECENT DEVELOPMENT 191

18 QUESTIONNAIRE 192

19 RELATED REPORTS 196

LIST OF TABLES

TABLE 1 EUROPE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 59
TABLE 2 EUROPE ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 60
TABLE 3 EUROPE UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 61
TABLE 4 EUROPE UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 65
TABLE 5 EUROPE CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 66
TABLE 6 EUROPE HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 68
TABLE 7 EUROPE PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 69
TABLE 8 EUROPE AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 70
TABLE 9 EUROPE LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 71
TABLE 10 EUROPE TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 72
TABLE 11 EUROPE MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 72
TABLE 12 EUROPE UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 77
TABLE 13 EUROPE BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 78
TABLE 14 EUROPE UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 83
TABLE 15 EUROPE UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 88
TABLE 16 EUROPE UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 93
TABLE 17 EUROPE HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 94
TABLE 18 EUROPE UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 99
TABLE 19 EUROPE RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 100
TABLE 20 EUROPE UTERINE CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 103
TABLE 21 GERMANY UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 104
TABLE 22 GERMANY ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 104
TABLE 23 GERMANY UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 104
TABLE 24 GERMANY UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 105
TABLE 25 GERMANY CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 105
TABLE 26 GERMANY HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 105
TABLE 27 GERMANY PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 106
TABLE 28 GERMANY AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 106
TABLE 29 GERMANY LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 106
TABLE 30 GERMANY TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 106
TABLE 31 GERMANY MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 107
TABLE 32 GERMANY UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 107
TABLE 33 GERMANY BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 107
TABLE 34 GERMANY UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 107
TABLE 35 GERMANY UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 108
TABLE 36 GERMANY UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 108
TABLE 37 GERMANY HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 108
TABLE 38 GERMANY UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 108
TABLE 39 GERMANY RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 109
TABLE 40 U.K. UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 110
TABLE 41 U.K. ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 110
TABLE 42 U.K. UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 110
TABLE 43 U.K. UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 110
TABLE 44 U.K. CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 111
TABLE 45 U.K. HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 111
TABLE 46 U.K. PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 111
TABLE 47 U.K. AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 111
TABLE 48 U.K. LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 112
TABLE 49 U.K. TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 112
TABLE 50 U.K. MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 112
TABLE 51 U.K. UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 112
TABLE 52 U.K. BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 113
TABLE 53 U.K. UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 113
TABLE 54 U.K. UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 113
TABLE 55 U.K. UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 113
TABLE 56 U.K. HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 114
TABLE 57 U.K. UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 114
TABLE 58 U.K. RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 114
TABLE 59 FRANCE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 115
TABLE 60 FRANCE ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 115
TABLE 61 FRANCE UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 115
TABLE 62 FRANCE UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 115
TABLE 63 FRANCE CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 116
TABLE 64 FRANCE HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 116
TABLE 65 FRANCE PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 116
TABLE 66 FRANCE AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 116
TABLE 67 FRANCE LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 117
TABLE 68 FRANCE TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 117
TABLE 69 FRANCE MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 117
TABLE 70 FRANCE UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 117
TABLE 71 FRANCE BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 118
TABLE 72 FRANCE UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 118
TABLE 73 FRANCE UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 118
TABLE 74 FRANCE UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 118
TABLE 75 FRANCE HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 119
TABLE 76 FRANCE UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 119
TABLE 77 FRANCE RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 119
TABLE 78 RUSSIA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 120
TABLE 79 RUSSIA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 120
TABLE 80 RUSSIA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 120
TABLE 81 RUSSIA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 120
TABLE 82 RUSSIA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 121
TABLE 83 RUSSIA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 121
TABLE 84 RUSSIA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 121
TABLE 85 RUSSIA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 121
TABLE 86 RUSSIA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 122
TABLE 87 RUSSIA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 122
TABLE 88 RUSSIA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 122
TABLE 89 RUSSIA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 122
TABLE 90 RUSSIA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 123
TABLE 91 RUSSIA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 123
TABLE 92 RUSSIA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 123
TABLE 93 RUSSIA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 123
TABLE 94 RUSSIA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 124
TABLE 95 RUSSIA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 124
TABLE 96 RUSSIA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 124
TABLE 97 ITALY UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 125
TABLE 98 ITALY ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 125
TABLE 99 ITALY UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 125
TABLE 100 ITALY UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 125
TABLE 101 ITALY CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 126
TABLE 102 ITALY HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 126
TABLE 103 ITALY PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 126
TABLE 104 ITALY AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 126
TABLE 105 ITALY LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 127
TABLE 106 ITALY TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 127
TABLE 107 ITALY MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 127
TABLE 108 ITALY UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 127
TABLE 109 ITALY BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 128
TABLE 110 ITALY UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 128
TABLE 111 ITALY UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 128
TABLE 112 ITALY UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 128
TABLE 113 ITALY HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 129
TABLE 114 ITALY UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 129
TABLE 115 ITALY RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 129
TABLE 116 SPAIN UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 130
TABLE 117 SPAIN ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 130
TABLE 118 SPAIN UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 130
TABLE 119 SPAIN UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 130
TABLE 120 SPAIN CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 131
TABLE 121 SPAIN HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 131
TABLE 122 SPAIN PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 131
TABLE 123 SPAIN AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 131
TABLE 124 SPAIN LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 132
TABLE 125 SPAIN TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 132
TABLE 126 SPAIN MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 132
TABLE 127 SPAIN UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 132
TABLE 128 SPAIN BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 133
TABLE 129 SPAIN UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 133
TABLE 130 SPAIN UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 133
TABLE 131 SPAIN UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 133
TABLE 132 SPAIN HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 134
TABLE 133 SPAIN UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 134
TABLE 134 SPAIN RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 134
TABLE 135 TURKEY UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 135
TABLE 136 TURKEY ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 135
TABLE 137 TURKEY UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 135
TABLE 138 TURKEY UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 135
TABLE 139 TURKEY CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 136
TABLE 140 TURKEY HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 136
TABLE 141 TURKEY PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 136
TABLE 142 TURKEY AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 136
TABLE 143 TURKEY LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 137
TABLE 144 TURKEY TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 137
TABLE 145 TURKEY MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 137
TABLE 146 TURKEY UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 137
TABLE 147 TURKEY BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 138
TABLE 148 TURKEY UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 138
TABLE 149 TURKEY UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 138
TABLE 150 TURKEY UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 138
TABLE 151 TURKEY HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 139
TABLE 152 TURKEY UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 139
TABLE 153 TURKEY RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 139
TABLE 154 BELGIUM UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 140
TABLE 155 BELGIUM ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 140
TABLE 156 BELGIUM UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 140
TABLE 157 BELGIUM UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 141
TABLE 158 BELGIUM CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 141
TABLE 159 BELGIUM HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 141
TABLE 160 BELGIUM PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 142
TABLE 161 BELGIUM AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 142
TABLE 162 BELGIUM LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 142
TABLE 163 BELGIUM TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 142
TABLE 164 BELGIUM MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 143
TABLE 165 BELGIUM UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 143
TABLE 166 BELGIUM BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 143
TABLE 167 BELGIUM UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 143
TABLE 168 BELGIUM UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 144
TABLE 169 BELGIUM UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 144
TABLE 170 BELGIUM HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 144
TABLE 171 BELGIUM UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 144
TABLE 172 BELGIUM RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 145
TABLE 173 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 146
TABLE 174 NETHERLANDS ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 146
TABLE 175 NETHERLANDS UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 146
TABLE 176 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 146
TABLE 177 NETHERLANDS CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 147
TABLE 178 NETHERLANDS HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 147
TABLE 179 NETHERLANDS PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 147
TABLE 180 NETHERLANDS AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 148
TABLE 181 NETHERLANDS LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 148
TABLE 182 NETHERLANDS TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 148
TABLE 183 NETHERLANDS MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 148
TABLE 184 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 149
TABLE 185 NETHERLANDS BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 149
TABLE 186 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 149
TABLE 187 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 149
TABLE 188 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 150
TABLE 189 NETHERLANDS HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 150
TABLE 190 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 150
TABLE 191 NETHERLANDS RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 150
TABLE 192 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 151
TABLE 193 SWITZERLAND ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 151
TABLE 194 SWITZERLAND UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 151
TABLE 195 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 152
TABLE 196 SWITZERLAND CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 152
TABLE 197 SWITZERLAND HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 152
TABLE 198 SWITZERLAND PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 153
TABLE 199 SWITZERLAND AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 153
TABLE 200 SWITZERLAND LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 153
TABLE 201 SWITZERLAND TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 153
TABLE 202 SWITZERLAND MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 154
TABLE 203 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 154
TABLE 204 SWITZERLAND BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 154
TABLE 205 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 154
TABLE 206 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 155
TABLE 207 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 155
TABLE 208 SWITZERLAND HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 155
TABLE 209 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 155
TABLE 210 SWITZERLAND RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 156
TABLE 211 REST OF EUROPE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 157

LIST OF FIGURES

FIGURE 1 EUROPE UTERINE CANCER DRUGS MARKET: SEGMENTATION 27
FIGURE 2 EUROPE UTERINE CANCER DRUGS MARKET: DATA TRIANGULATION 29
FIGURE 3 EUROPE UTERINE CANCER DRUGS MARKET: DROC ANALYSIS 30
FIGURE 4 EUROPE UTERINE CANCER DRUGS MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS 31
FIGURE 5 EUROPE UTERINE CANCER DRUGS MARKET: COMPANY RESEARCH ANALYSIS 31
FIGURE 6 EUROPE UTERINE CANCER DRUGS MARKET: INTERVIEW DEMOGRAPHICS 33
FIGURE 7 EUROPE UTERINE CANCER DRUGS MARKET: DBMR MARKET POSITION GRID 34
FIGURE 8 EUROPE UTERINE CANCER DRUGS MARKET: MARKET END USER COVERAGE GRID 35
FIGURE 9 EUROPE UTERINE CANCER DRUGS MARKET: VENDOR SHARE ANALYSIS 36
FIGURE 10 EUROPE UTERINE CANCER DRUGS MARKET: SEGMENTATION 40
FIGURE 11 RISING INCIDENCE OF UTERINE CANCER IS DRIVING THE GROWTH OF THE EUROPE UTERINE CANCER DRUGS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030 41
FIGURE 12 THE ENDOMETRIAL CANCER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE UTERINE CANCER DRUGS MARKET IN THE FORECAST PERIOD OF 2023 AND 2030 41
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE UTERINE CANCER DRUGS MARKET 45
FIGURE 14 EUROPE UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, 2022 57
FIGURE 15 EUROPE UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, 2023-2030 (USD THOUSAND) 58
FIGURE 16 EUROPE UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, CAGR (2023-2030) 58
FIGURE 17 EUROPE UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, LIFELINE CURVE 59
FIGURE 18 EUROPE UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, 2022 63
FIGURE 19 EUROPE UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND) 64
FIGURE 20 EUROPE UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, CAGR (2023-2030) 64
FIGURE 21 EUROPE UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, LIFELINE CURVE 65
FIGURE 22 EUROPE UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, 2022 75
FIGURE 23 EUROPE UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, 2023-2030 (USD THOUSAND) 76
FIGURE 24 EUROPE UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, CAGR (2023-2030) 76
FIGURE 25 EUROPE UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, LIFELINE CURVE 77
FIGURE 26 EUROPE UTERINE CANCER DRUGS MARKET: BY AGE GROUP, 2022 81
FIGURE 27 EUROPE UTERINE CANCER DRUGS MARKET: BY AGE GROUP, 2023-2030 (USD THOUSAND) 82
FIGURE 28 EUROPE UTERINE CANCER DRUGS MARKET: BY AGE GROUP, CAGR (2023-2030) 82
FIGURE 29 EUROPE UTERINE CANCER DRUGS MARKET: BY AGE GROUP, LIFELINE CURVE 83
FIGURE 30 EUROPE UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2022 86
FIGURE 31 EUROPE UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND) 87
FIGURE 32 EUROPE UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030) 87
FIGURE 33 EUROPE UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 88
FIGURE 34 EUROPE UTERINE CANCER DRUGS MARKET: BY END USER, 2022 91
FIGURE 35 EUROPE UTERINE CANCER DRUGS MARKET: BY END USER, 2023-2030 (USD THOUSAND) 92
FIGURE 36 EUROPE UTERINE CANCER DRUGS MARKET: BY END USER, CAGR (2023-2030) 92
FIGURE 37 EUROPE UTERINE CANCER DRUGS MARKET: BY END USER, LIFELINE CURVE 93
FIGURE 38 EUROPE UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022 97
FIGURE 39 EUROPE UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 98
FIGURE 40 EUROPE UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 98
FIGURE 41 EUROPE UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 99
FIGURE 42 EUROPE UTERINE CANCER DRUGS MARKET: SNAPSHOT (2022) 101
FIGURE 43 EUROPE UTERINE CANCER DRUGS MARKET: COMPANY SHARE 2022 (%) 158